Context Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 5
- Market Cap
- $187.4M
- Introduction
Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone exten...
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Context Therapeutics Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT06515613
- Locations
- 🇺🇸
Context Investigational Site, Dallas, Texas, United States
Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer
- First Posted Date
- 2022-11-16
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Context Therapeutics Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT05618613
- Locations
- 🇺🇸
Cancer Treatment Centers of America - Western Regional Medical Center, Phoenix, Arizona, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸Cancer Treatment Centers of America - Midwestern Regional Center, Zion, Illinois, United States
© Copyright 2024. All Rights Reserved by MedPath